Images |
Sources |
Experiment + Assay |
Phenotypes |
Human Diseases |
|
Fig. 1 DE
Kreis J et al. (2022)
|
Xla Wt + rab7a MO
NF10-11 (in situ hybridization)
|
|
|
|
Fig. 2 B-G
Kreis J et al. (2022)
|
Xla Wt + rab7a MO
NF10-11 (in situ hybridization)
|
|
|
|
Fig 2 H-J
Kreis J et al. (2022)
|
Xla Wt + rab7a MO
NF10-11 (in situ hybridization)
|
|
|
|
Fig. 3 B B' D F H
Kreis J et al. (2022)
|
Xla Wt + rab7a MO
NF10-11 (in situ hybridization)
|
|
|
|
Fig. 3 J L N P
Kreis J et al. (2022)
|
Xla Wt + rab7a MO
NF10-11 (in situ hybridization)
|
|
|
|
Fig. 3 S S'S"
Kreis J et al. (2022)
|
Xla Wt + rab7a MO
NF12.5 (immunohistochemistry)
|
|
|
|
Fig. 2 K-R
Kreis J et al. (2022)
|
Xla Wt + rab7a MO
NF17 (in situ hybridization)
|
|
|
|
FIG 2 S'
Kreis J et al. (2022)
|
Xla Wt + rab7a MO
NF17 (in situ hybridization)
|
|
|
|
Fig 1 M
Kreis J et al. (2022)
|
Xla Wt + rab7a MO (0.8pmol)
NF32 (in situ hybridization)
|
|
|
|
Fig. 2 I J J'
Kreis J et al. (2021)
|
Xla Wt + rab7a MO
NF10-11.5 (in situ hybridization)
|
|
|